Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
Project Summary Abstract:
Influenza vaccination is the most effective means of preventing influenza virus infection and its more severe
complications. Due to the changing nature of influenza viruses, active surveillance alongside regular updating
of vaccine components and annual vaccination are necessary for vaccine protection. There is a need for
annual evaluation of vaccine effectiveness (VE), which may vary from year to year. These estimates are critical
to inform the medical community, maintain public confidence in the vaccine, and determine the effect of virus
drift on protection. Modern study designs to assess VE require laboratory confirmation of influenza infection,
sensitive and specific measures of vaccine receipt, and the use of a case test-negative design to control for
differences in healthcare-seeking behavior between vaccinated and unvaccinated patients. We propose to use
these methods to estimate influenza VE in preventing influenza-associated ambulatory care visits in two health
systems in Michigan, where we have been conducting annual assessments of VE since 2008. We will conduct
surveillance at adult and pediatric outpatient clinics, and we will enroll patients seeking care for acute
respiratory infections meeting a standard case definition. Vaccination status will be reported and documented,
and considered with laboratory-confirmed influenza outcomes to estimate VE in preventing influenza-
associated health care visits. Analyses will use the case test-negative design; those testing positive for
influenza will be cases, those testing negative will be controls. Modifiers and confounders of VE such as age,
health status, high-risk health conditions, education, time from illness onset to specimen collection, and
calendar time will be assessed. We will also estimate the population-based incidence of medically-attended
influenza and will identify infections due to respiratory syncytial virus (RSV) and other respiratory viruses in
later years of the study. We will pilot methods to monitor the development of influenza virus resistance to
antiviral medications which could inform similar studies carried out in a potential future influenza pandemic. In
addition to our proposed influenza surveillance and VE assessment in the outpatient setting, we propose to
continue our analyses of influenza VE and development of influenza antibodies among a prospectively
followed cohort of households with children which has been in place since 2010. This cohort will be used to
carry out complementary analyses of VE in preventing influenza illnesses of any severity which will be
identified through ongoing active surveillance. Households in this cohort are followed for multiple years,
enabling precise evaluations of repeated vaccination. Our current enrollment strategies will be augmented with
targeted enrollment of households with children under age 3. Blood specimens will be collected from adults
and children twice yearly; a third blood specimen will be collected from children < 3 years old 4 weeks after
vaccination. The proposed work will enable the continuation of our established, coordinated, multi-faceted
evaluation of influenza VE and development of antibodies in both ambulatory and community settings.
Public Health Relevance Statement
Project Narrative
The proposed research is relevant to public health because of the need for current estimates of influenza
vaccine effectiveness (VE) in preventing medically attended influenza using laboratory-confirmed outcomes
and case test-negative study design. We propose estimation of influenza VE in preventing influenza-
associated ambulatory care visits in two health systems in Michigan, where we have been conducting annual
assessments of VE in various populations since 2008; additionally we will evaluate influenza VE and
development of influenza antibodies in a cohort of households with children. This research is relevant to the
mission of the CDC Influenza Division in that it will inform efforts to guide vaccination and control policies and
improve initiatives to prevent severe illness resulting from influenza infection.
National Center for Immunization and Respiratory Diseases
CFDA Code
185
DUNS Number
073133571
UEI
GNJ7BBP73WE9
Project Start Date
01-August-2016
Project End Date
31-July-2021
Budget Start Date
01-August-2017
Budget End Date
31-July-2018
Project Funding Information for 2017
Total Funding
$1,299,999
Direct Costs
$892,282
Indirect Costs
$407,717
Year
Funding IC
FY Total Cost by IC
2017
National Center for Immunization and Respiratory Diseases
$1,299,999
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U01IP001034-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01IP001034-02
Patents
No Patents information available for 5U01IP001034-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01IP001034-02
Clinical Studies
No Clinical Studies information available for 5U01IP001034-02
News and More
Related News Releases
No news release information available for 5U01IP001034-02
History
No Historical information available for 5U01IP001034-02
Similar Projects
No Similar Projects information available for 5U01IP001034-02